Combination Therapy for Liver Metastases Resulting from Colorectal Cancer
Name of the Trial
Why Is This Trial Important?
The only curative treatment available for liver metastases resulting from colorectal cancer is surgical removal (resection). However, most patients are not eligible for tumor resection because of the size, number, or location of their metastases.
In this study, researchers are combining local treatment of liver metastases through isolated hepatic perfusion (IHP) and standard systemic chemotherapy to determine whether this combined approach may prolong patients' lives. In IHP, the flow of blood to and from the liver is temporarily isolated from the rest of the body so that high doses of anticancer drugs, such as melphalan, can be delivered to the liver while sparing other tissues. Response rates to IHP in other clinical trials have been promising, with significant regression of visible metastases occurring in many patients.
However, patients with liver metastases are at high risk of having developed undetectable (occult) metastases elsewhere in the body. The researchers hope that following IHP with systemic chemotherapy may not only enhance the effects of IHP on detectable liver metastases but also eradicate occult metastatic tumors.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.